Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation

Analyst Thomas Shrader from BTIG maintained a Buy rating on Bright Minds Biosciences and keeping the price target at $147.00.

Thomas Shrader has given his Buy rating due to a combination of factors including the strong clinical profile of BMB-101 in difficult-to-treat epilepsies. He highlights that adult absence seizure patients are highly refractory, current therapies are limited, and even partial seizure reductions can materially improve quality of life in a setting where true seizure freedom is rare but increasingly valued.

He also points to BMB-101’s recent Phase 2 data showing substantial seizure reductions in both absence and DEE cohorts, alongside a favorable safety profile and lack of troubling somnolence effects, which differentiates it from existing options. In addition, he views the planned Prader-Willi syndrome trial as a meaningful upside opportunity supported by a mechanism aligned with physician needs, and notes that the company’s rapid clinical progress supports a favorable DCF-based valuation for the stock.